Jean‐Pierre Riveline, Jean‐Baptiste Julla, Élisabeth Bonnemaison, Michaël Joubert, Sandrine Lablanche, Agnès Sola Gazagnes, Delphine Demarsy, D. Gouet, Pauline Schaepelynck, Chloé Amouyal, Fabienne Dalla Vale, Anne Schletzer‐Mari, Sylvaine Clavel, Anne Spiteri, Catherine Campinos, Sandrine Favre, Igor Tauveron, Laurence Mathivon, Sophie Borot, Guy Fagherazzi, Marc D. Breton, Jean–François Gautier, Éric Renard, for the OB2F study group
AIMS: A nationwide observational study was conducted to assess the 12-month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D). METHODS: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9-10 mmol/L) after 1 year with AID. RESULTS: [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7%, Tandem Control-IQ in 49.3%, others in 1%. After 12 months, TIR increased from 58.0 [21] to 70.1% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9%, and ketoacidosis from 1.2 to 0.6%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant (p < 0.05). Only 2.8% of PwT1D discontinued AID. CONCLUSIONS: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.